Free Trial

International Stem Cell (ISCO) Stock Price, News & Analysis

+0.03 (+44.12%)
(As of 07/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
1,423 shs
Average Volume
1,308 shs
Market Capitalization
P/E Ratio
Dividend Yield
Price Target
ISCO stock logo

About International Stem Cell Stock (OTCMKTS:ISCO)

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC- hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke and traumatic brain injury. The company also offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner. In addition, it provides human cell culture products comprising human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. International Stem Cell Corporation was founded in 2001 and is headquartered in San Diego, California.

ISCO Stock Price History

ISCO Stock News Headlines

International Stem Cell Corporation (ISCO)
270x more lucrative than NVIDIA???
Is the AI boom losing steam? According to the Wall Street Journal, the pace of innovation in AI is slowing down... Its usefulness is limited... And the cost of running AI remains "exorbitant."
270x more lucrative than NVIDIA???
Is the AI boom losing steam? According to the Wall Street Journal, the pace of innovation in AI is slowing down... Its usefulness is limited... And the cost of running AI remains "exorbitant."
International Stem Cell Corp ISCO
See More Headlines
Receive ISCO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for International Stem Cell and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$7.79 million
Book Value
($0.57) per share


Free Float
Not Optionable
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Andrey Semechkin Ph.D. (Age 64)
    Co-Chairman of the Board & CEO
    Comp: $66.56k
  • Dr. Russell Kern Ph.D. (Age 38)
    Executive VP, Chief Scientific Officer, Principal Financial Officer & Director
    Comp: $140k
  • Ms. Rebecca McGee M.B.A.
    President of Lifeline Cell Technology

ISCO Stock Analysis - Frequently Asked Questions

How have ISCO shares performed this year?

International Stem Cell's stock was trading at $0.0620 on January 1st, 2024. Since then, ISCO stock has increased by 58.1% and is now trading at $0.0980.
View the best growth stocks for 2024 here

How were International Stem Cell's earnings last quarter?

International Stem Cell Co. (OTCMKTS:ISCO) issued its quarterly earnings data on Tuesday, May, 14th. The biotechnology company reported ($0.03) earnings per share for the quarter. The biotechnology company earned $2.13 million during the quarter.

How do I buy shares of International Stem Cell?

Shares of ISCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of International Stem Cell own?

Based on aggregate information from My MarketBeat watchlists, some other companies that International Stem Cell investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Athersys (ATHX), Turkcell Iletisim Hizmetleri A.S. (TKC), Biocept (BIOC), Capricor Therapeutics (CAPR) and

This page (OTCMKTS:ISCO) was last updated on 7/23/2024 by Staff

From Our Partners